It doesn't matter how many links there are between indications. I've always been told not to invest if you cannot handle simple principles such as time management.
If you cannot understand time management then perhaps you should invest elsewhere.
The only way that your argument makes sense is if one trial could serve all CNS indications. Since they are all separate trials they are all separate beasts. They all have separate approval appoints, separate tests, separate sites, and many other factors that I don't need to go into.
Market Data 
Markets 
AI
